Earnings Call Summary | Biolase(BIOL.US) Q1 2024 Earnings Conference
Earnings Call Summary | Biolase(BIOL.US) Q1 2024 Earnings Conference
The following is a summary of the BIOLASE, Inc. (BIOL) Q1 2024 Earnings Call Transcript:
以下是BIOLASE, Inc.（BIOL）2024年第一季度業績電話會議記錄摘要：
Financial Performance:
財務業績：
BIOLASE reported a significant growth in consumable sales, marking a 14% increase compared to the same quarter last year, making it one of the strongest quarters in the company's history.
The company achieved a reduction in its adjusted EBITDA loss by 21%, demonstrating improved financial discipline and operational efficiency.
The CEO, John Beaver, expressed optimism towards achieving profitability by the end of the year.
BIOLASE ended the first quarter with a cash balance of $6.4 million and expects to report positive adjusted EBITDA for the full year of 2024.
BIOLASE報告稱，消耗品銷售大幅增長，與去年同期相比增長了14％，成爲該公司歷史上最強勁的季度之一。
該公司調整後的息稅折舊攤銷前利潤虧損減少了21％，這表明財務紀律和運營效率得到改善。
首席執行官約翰·比弗對年底之前實現盈利表示樂觀。
BIOLASE在第一季度末的現金餘額爲640萬美元，預計2024年全年調整後的息稅折舊攤銷前利潤將爲正數。
Business Progress:
業務進展：
A significant portion of BIOLASE's U.S. Waterlase sales (67%) for the quarter was to new customers, with dental specialists accounting for about 42% of these sales.
The company organized and participated in over a hundred promotional events, ranging from webinars to trade shows, aimed at promoting the benefits of laser dentistry.
BIOLASE continued to roll out their unique Waterlase and EPIC academy training programs.
The company's ongoing commercial focus remains on reaching to the estimated 90% of dentists who are yet to adopt all-tissue laser technology.
In the future, the company plans to allocate investments towards revenue-generating activities.
For 2024, BIOLASE has projected a year-over-year revenue growth ranging from 6% to 8%, translating to an estimated full year revenue of between $52 million to $53 million.
BIOLASE本季度美國Waterlase銷售額的很大一部分（67％）來自新客戶，牙科專家約佔這些銷售額的42％。
該公司組織並參與了一百多場促銷活動，從網絡研討會到貿易展覽會，旨在宣傳激光牙科的好處。
BIOLASE繼續推出其獨特的Waterlase和EPIC學院培訓計劃。
該公司持續的商業重點仍然是向尚未採用全組織激光技術的估計90％的牙醫提供服務。
將來，該公司計劃將投資分配給創收活動。
BIOLASE預計2024年的收入同比增長6％至8％不等，這意味着全年收入估計在5200萬美元至5300萬美元之間。
More details: Biolase IR
更多詳情： Biolase IR
Tips: For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.
提示：欲了解更多詳情，請訪問投資者關係網站。本文僅供投資者參考，不構成任何投資建議。
譯文內容由第三人軟體翻譯。